Robert W. Baird Issues Positive Forecast for Medpace (NASDAQ:MEDP) Stock Price

Medpace (NASDAQ:MEDP) had its target price hoisted by Robert W. Baird from $547.00 to $624.00 in a report released on Friday morning, Marketbeat Ratings reports. The brokerage currently has a neutral rating on the stock.

MEDP has been the subject of several other reports. Leerink Partners set a $620.00 price objective on Medpace in a report on Thursday. Barclays set a $600.00 target price on shares of Medpace in a research note on Thursday. Weiss Ratings reiterated a “hold (c+)” rating on shares of Medpace in a research report on Thursday, July 2nd. Wall Street Zen downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, Royal Bank Of Canada cut their price objective on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Two investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $560.92.

Medpace Stock Performance

NASDAQ MEDP opened at $601.38 on Friday. The stock has a fifty day moving average of $492.09 and a 200-day moving average of $494.49. The stock has a market capitalization of $17.18 billion, a P/E ratio of 35.25, a price-to-earnings-growth ratio of 2.96 and a beta of 1.15. Medpace has a 52 week low of $373.00 and a 52 week high of $677.90.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. During the same quarter in the previous year, the company posted $3.10 earnings per share. The firm’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities research analysts forecast that Medpace will post 17.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel owned 20,343 shares in the company, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 20.50% of the company’s stock.

Institutional Trading of Medpace

A number of institutional investors and hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC boosted its stake in Medpace by 65.1% during the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after acquiring an additional 404,226 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in Medpace by 205.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock valued at $161,523,000 after purchasing an additional 211,411 shares in the last quarter. Franklin Resources Inc. raised its holdings in Medpace by 158.6% in the fourth quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock worth $168,198,000 after purchasing an additional 183,645 shares during the period. Norges Bank acquired a new stake in Medpace in the fourth quarter worth $102,156,000. Finally, Goldman Sachs Group Inc. raised its holdings in Medpace by 92.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 347,049 shares of the company’s stock worth $194,920,000 after purchasing an additional 166,654 shares during the period. 77.98% of the stock is owned by institutional investors.

Trending Headlines about Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace reported stronger-than-expected Q2 results, with EPS of $4.25 topping estimates and revenue of $707.3 million exceeding forecasts, reinforcing momentum in the business. MarketWatch article
• Positive Sentiment: The company raised FY 2026 guidance to EPS of $17.25-$17.95 and revenue of about $2.8 billion-$2.9 billion, signaling confidence in continued growth and backlog conversion. Benzinga article
• Positive Sentiment: Bookings and backlog trends improved, with commentary highlighting a rebound in the net book-to-bill ratio and better revenue visibility, which supports investor optimism about future quarters. Seeking Alpha article
• Neutral Sentiment: Truist raised its price target to $609 from $462 but kept a hold rating, while Robert W. Baird lifted its target to $624 and maintained a neutral stance, suggesting analysts see upside but are not turning fully bullish. Benzinga article
• Neutral Sentiment: The stock’s move to a 52-week high reflects strong recent performance, but one Zacks note questioned whether the rally can continue, indicating the market may now be weighing valuation against the improved fundamentals. Zacks article

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.